Great Point Partners’s Sagimet Biosciences SGMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.4M Sell
1,961,701
-68,232
-3% -$627K 4.63% 5
2026
Q2
$15.7M Buy
+2,029,933
New +$13.8M 2.97% 14

Other funds holding SGMT

Great Point Partners's SGMT Position: Q3 2026 in Review

Great Point Partners reduced its Sagimet Biosciences (SGMT) stake by 3.4% in Q3 2026, selling an estimated $627K and leaving 1,961,701 shares worth $19.4M. The position accounts for 4.63% of the portfolio, ranked #5.

Great Point Partners first reported a position in SGMT in Q2 2026 and has held it in 2 quarters since. 153 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

  • Great Point Partners held 1,961,701 shares of Sagimet Biosciences worth $19.4M as of Q3 2026.
  • Great Point Partners sold 68,232 Sagimet Biosciences shares in Q3 2026, an estimated $627K.
  • Sagimet Biosciences made up 4.63% of Great Point Partners's portfolio in Q3 2026, its #5 holding.
  • Great Point Partners first reported a position in Sagimet Biosciences in Q2 2026 and has held it in 2 quarters since.
  • 153 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on Great Point Partners's 13F filing for Q3 2026, filed 16 Nov 2026.